DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01832532

CompletedPhase 1, PHASE2Results posted

A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks

Pilot 2: Glucagon-like Peptide-1 in Sleep Disordered Breathing

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

34

actual

Study population

Obesity / overweight, Sleep apnea

Key I/E criterion

•BMI ≥27

Primary endpoint

•AHI, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01832532
Org study IDCIN001Pilot 2GLP
Secondary IDUL1RR026314

Timeline

Milestones

Study first posted2013-04-16estimated
Last update posted2020-10-20actual
Results first posted2020-10-20actual
Study start2013-04 (month precision)
Primary completion2015-12actual (month precision)
Study completion2015-12actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightSleep apnea

Eligibility

Who can enroll

Minimum age18 Years
Maximum age60 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Age 18-60 years
•Diagnosis of severe obstructive sleep apnea (OSA) AHI ≥ 8 /hour of sleep
•Ability and willingness to comply with all protocol procedures e.g. correct handling of trial product, compliance to visit schedule
•BMI of ≥ 27
•For Cohort 1: If female of childbearing capacity, willing to use acceptable birth control during use of study drug

Exclusion criteria

•A major medical condition such as renal or hepatic failure
•Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors or insulin within the last 3 months prior to screening
•Diagnosis of type 1 or type 2 diabetes per judgment of the investigator
•BMI < 27
•History of glycosylated hemoglobin (HbA1c) equal to or above 6.5%
•Significant craniofacial abnormalities that may cause OSA
•Respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator
•Use of central stimulants, hypnotics, mirtazepine, opioids, trazodone or drugs in the incretin family within the previous 3 months prior to screening
•Previous surgical treatment for obesity
•Familial or personal history of Multiple Endocrine Neoplasia type 2 or familial Medullary Thyroid Carcinoma
•Personal or immediate family history of thyroid cancer
•History of chronic pancreatitis or idiopathic acute pancreatitis
•History of Major Depressive Disorder or suicide attempts
•Systolic blood pressure equal to or above 160 mmHg and/or diastolic blood pressure equal to or above 100 mmHg
•History of alcoholism
•Pregnancy or breastfeeding

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other clinical outcomes

2 endpoints
Primary/registry result

Change in Apnea Hypopnea Index (AHI) From Baseline

Time frame:Baseline and 4 weeks

AHI, change

change from baseline, improvement

Posted result

GroupValue (mean), apnea / hypopnea events per hour sleep95% CI
Treatment Group- Liraglutide38.2—
Control Group34—
Primary/protocol endpoint

Change in Apnea Hypopnea Index (AHI) From Baseline

Time frame:Baseline and 4 weeks

AHI, change

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.